Bone Tumors Pathology — Benign and Malignant

Mechanisms of Benign Bone Tumors

• Osteochondroma (Hereditary Multiple Osteochondromas—HMO): Results from dysregulation of endochondral ossification at the growth plate periphery, characterized by aberrant cartilage cap that undergoes normal enchondral ossification with transition to mature lamellar bone. Mutations in EXT1/EXT2 genes (encoding heparan sulfate biosynthesis enzymes) prevent normal cartilage matrix remodeling and growth plate containment, leading to progressive exostosis formation; lesions are typically solitary but become multiple when inherited. Growth generally ceases at skeletal maturity when physeal plates close, though malignant transformation occurs in 1-5% of hereditary cases (higher than sporadic 1%), likely due to continuous dysregulation of growth signaling.

• Giant Cell Tumor (GCT) of Bone: Arises from neoplastic mononuclear stromal cells that aberrantly recruit and stimulate multinucleated osteoclast-like giant cells through RANKL (receptor activator of NF-κB ligand) overexpression. The characteristic "soap bubble" or "honeycomb" lytic appearance reflects zones of active osteoclast-mediated bone resorption interspersed with fibrous and fibroblastic tissue. Somatic mutations in H3F3A (histone 3.3) at codon 120 (K120M mutation) are present in ~98% of cases, driving oncogenic signaling and RANKL production; the tumor behaves as a latent neoplasm with local aggressive potential (marginal or wide margins necessary) and low metastatic risk (~5% pulmonary mets, usually late).

• Osteoid Osteoma and Osteoblastoma: Share benign osteoid/bone-producing differentiation but represent a spectrum. Osteoid osteoma is smaller (<2 cm), self-limited, and produces intense nocturnal pain dramatically relieved by NSAIDs due to prostaglandin E2 (PGE2) production by the nidus; pain relates to inflammatory mediators and nerve sensitization rather than mass effect. Osteoblastoma is larger (>2 cm), more aggressive, may enlarge progressively, and occurs in different skeletal sites; both show surrounding reactive sclerosis on imaging (though osteoblastoma may be purely lytic), and histologically feature benign osteoblasts rimming irregular trabeculae of osteoid and woven bone within a fibrovascular stroma.

Mechanisms of Malignant Bone Tumors

• Osteosarcoma (High-Grade Intramedullary Osteosarcoma): The most common primary malignant bone tumor in children/young adults, arising from transformed osteoblasts that produce malignant osteoid and bone in a chaotic, infiltrative pattern. Pathogenesis involves biallelic inactivation of TP53 (most frequent genetic event, present in ~50% of sporadic cases and nearly 100% of Li-Fraumeni syndrome-associated osteosarcomas) and concurrent dysregulation of RB1 pathway (through direct mutation or through p16/CDK4/Cyclin D1 alterations), generating cells with impaired apoptosis and unchecked proliferation. Additional mechanisms include increased osteoblastic activity driven by IGF-1 signaling and angiogenesis promoting tumor neovascularization; the tumor rapidly breaks through the cortex and periosteum, often elevating periosteum and forming Codman triangle (reactive periosteal new bone at margin of tumor breakthrough), and demonstrates marked local invasion with skip lesions (discontinuous tumor foci within medullary canal). High-grade osteosarcoma is inherently systemic at presentation in ~80% of cases with micrometastases, primarily to lungs, though clinical metastases are evident in only ~20% at diagnosis, necessitating staging imaging.

• Ewing Sarcoma (PNET): An aggressive round cell malignancy arising from an undifferentiated mesenchymal precursor, characterized by the pathognomonic t(11;22)(q24;q12) translocation (or variant translocations in ~10% of cases—t(21;22) or others) that fuses the EWSR1 gene on chromosome 22 with FLI1 on chromosome 11, generating an aberrant oncogenic transcription factor. The EWS-FLI1 fusion protein drives aberrant transcription of oncogenic targets (including direct upregulation of PDGF and NKX2.2) and repression of tumor suppressors, causing rapid, undifferentiated proliferation; the tumor presents as a diaphyseal or metadiaphyseal lesion (unlike osteosarcoma's metaphyseal predilection), with a predilection for femur, pelvis, and tibia in adolescent/young adult males, and classically demonstrates "onion skin" periosteal reaction (alternating layers of reactive bone and tumor breakthrough). Molecular pathology demonstrates uniform small round cells with scant cytoplasm and round nuclei, minimal differentiation (distinguishing it from osteosarcoma's osteoid production), and high mitotic activity; the tumor is inherently aggressive with early hematogenous spread (similar to osteosarcoma) to lungs, bones, and bone marrow.

• Chondrosarcoma: Represents malignant cartilage production by dysplastic chondrocytes, with pathogenic mechanisms varying by grade and origin. Low-grade lesions arise from malignant transformation of osteochondroma or enchondroma and progress through acquisition of p16/CDK4/RB pathway alterations and mutations in IDH1/IDH2 genes (in enchondroma-derived tumors); central (medullary) chondrosarcomas arise de novo whereas peripheral (surface) variants develop from preexisting cartilage lesions. Histological grade reflects cellularity, nuclear pleomorphism, and mitotic activity, directly correlating with biologic behavior; high-grade tumors show infiltrative growth with invasion through cortex and soft tissue, whereas low-grade lesions may appear innocuous histologically but demonstrate progressive enlargement and cortical breakthrough on imaging.

Benign Bone Tumors

• Hereditary Multiple Osteochondromas (HMO): Autosomal dominant inheritance with EXT1 (chromosome 8q24) or EXT2 (chromosome 11p12) mutations; represents 10-15% of osteochondroma cases, with ~30-fold increased malignant transformation risk compared to sporadic lesions
• Giant Cell Tumor: Sporadic somatic H3F3A K120M mutation (98% of cases); rare familial clustering reported but no clear germline predisposition
• Osteoid Osteoma: No clear genetic predisposition; rare familial cases suggest possible low-penetrance mutations; no environmental risk factors established
• Osteoblastoma: Similarly sporadic with rare familial aggregation; possible shared genetic susceptibility with osteoid osteoma

Malignant Bone Tumors

• Osteosarcoma: TP53 mutations (germline in Li-Fraumeni syndrome [LFS]—up to 90% lifetime risk of various malignancies including osteosarcoma) and RB1 mutations (hereditary retinoblastoma with ~500-fold increased risk); additional risk from prior radiation therapy (secondary osteosarcoma arising in irradiated fields), chemotherapy exposure (particularly alkylating agents), and Paget disease of bone (<1% malignant transformation risk). Rapid skeletal growth correlates with increased risk (evidenced by peak incidence in second decade coinciding with pubertal growth spurt).

• Ewing Sarcoma: t(11;22) translocation present in >90% of cases; essentially all cases arise de novo (no familial predisposition identified), though rare cases associated with germline chromosomal rearrangements. Secondary Ewing sarcoma extremely rare; no established role for prior radiation or chemotherapy in pathogenesis (unlike secondary osteosarcoma).

• Chondrosarcoma: Malignant transformation of preexisting benign lesions (osteochondroma in HMO or enchondroma), with increased risk in multiple hereditary exostoses (MHE) patients. IDH1/IDH2 mutations (particularly in central chondrosarcoma and enchondroma-derived tumors) correlate with histological grade and aggressiveness. Ollier disease (multiple enchondromatosis) and Maffucci syndrome (enchondromatosis with hemangiomas) confer ~100% lifetime risk of chondrosarcoma development.

Benign Bone Tumors

• Osteochondroma (Exostosis):
• Painless bony prominence, often detected incidentally on imaging or during physical examination; if symptomatic, pain results from mechanical irritation (bursa formation, nerve/vessel compression, or impingement on adjacent structures—the "bursa sign")
• Family history of multiple exostoses in hereditary cases
• Physical exam: firm, non-tender bony mass with immobility relative to underlying bone; surface contour may be smooth or irregular
• Imaging correlate: sessile or pedunculated bony lesion with cortical and medullary continuity with parent bone; cartilage cap may be visualized on MRI
• Growth cessation typically occurs at skeletal maturity; unusual growth in adults should raise suspicion for malignant transformation

• Giant Cell Tumor of Bone:
• Dull, aching, progressive pain is cardinal symptom; localized swelling and functional impairment related to location (especially around knee where most common)
• Typically affects young adults (20-40 years), almost exclusively arising epiphyseal or epiphyseal-metaphyseal region of long bones (distal femur, proximal tibia, distal radius); ~60% occur around knee
• Physical exam: swelling, effusion (if intra-articular or adjacent to joint), limitation of motion; warmth and erythema less common than with inflammatory arthritis
• Imaging: radiolucent ("lytic") lesion reaching subarticular cortex (eccentric location common), often with soap bubble or honeycomb appearance reflecting locules of variable density separated by septa; MRI shows hemosiderin deposition indicating prior hemorrhage/necrosis

• Osteoid Osteoma:
• Pathognomonic: severe nocturnal pain that is dramatically relieved (within 30 minutes to 1 hour) by NSAIDs, particularly aspirin; pain is often most severe at night and may awaken patient from sleep; relief is so consistent that absence of NSAID response should prompt diagnostic reconsideration
• Localized swelling and warmth may develop; if lesion is near joint, secondary synovitis and joint effusion can occur
• Physical exam: point tenderness over lesion site; muscle atrophy may develop if pain has been chronic; scoliosis can develop if lesion is in spine (pain-induced postural deformity)
• Imaging: small radiolucent nidus (typically <2 cm) surrounded by reactive sclerosis and periosteal thickening; nidus may be difficult to visualize on plain films but is typically evident on CT (appears as small lucency with calcification); MRI shows surrounding marrow and soft tissue edema disproportionate to lesion size

• Osteoblastoma:
• Pain similar to osteoid osteoma but may be less responsive to NSAIDs and more variable; mass effect symptoms (swelling, functional impairment) more prominent than with osteoid osteoma
• Affects slightly older patients (typically 10-30 years) and shows different anatomic distribution (more common in posterior elements of spine and pelvis, whereas osteoid osteoma favors diaphysis/metaphysis of long bones)
• Physical exam: visible or palpable swelling; if in spine, may present with scoliosis, kyphosis, or neurological deficits from mass effect
• Imaging: larger lytic lesion (>2 cm) with variable periosteal reaction; may be purely lytic (especially if medullary), causing diagnostic confusion with more aggressive lesions; surrounding soft tissue mass and edema common

Malignant Bone Tumors

• Osteosarcoma:
• Progressive pain and swelling of metaphyseal region of long bone; pain is often initially attributed to trauma or "growing pains" in adolescents, causing diagnostic delay
• Constitutional symptoms (fever, weight loss) absent at presentation unless extensive soft tissue involvement or systemic metastases
• Physical exam: firm, warm, tender mass with overlying skin erythema; soft tissue fullness indicating extraosseous tumor extension; reduced motion of adjacent joint; pulses and sensory examination may be abnormal if major neurovascular structures are invaded
• Pain is unrelated to activity and present at rest/night (distinguishing from mechanical causes); may be acute in onset (following pathological fracture) or insidious
• Imaging correlates: metaphyseal origin (distal femur, proximal tibia, proximal humerus most common—the "around the knee" rule); mixed lytic and sclerotic lesion with cortical breakthrough, Codman triangle (periosteal reaction where elevated periosteum is lifted at tumor margin, calcifying in layers), sunburst or radiating spicule pattern (radiating spicules of new bone formation perpendicular to cortex); soft tissue mass evident on MRI/CT; skip lesions (discontinuous tumor foci in medullary canal) present in ~5% of cases
• Systemic staging essential: PET-CT and chest CT (lungs in ~80% of metastatic cases); bone scan or skeletal scintigraphy to detect osseous metastases

• Ewing Sarcoma:
• Severe, progressive pain and swelling often with brief symptom duration (weeks to a few months at presentation); pain may be more pronounced at night
• B symptoms: fever, chills, and night sweats in ~25% of cases (mimicking infection); elevated inflammatory markers (CRP, ESR) common, potentially suggesting osteomyelitis and causing initial diagnostic confusion
• Physical exam: firm, tender, warm mass (warmth and erythema may mimic cellulitis); overlying skin may be erythematous and warm; systemic fever common; limp or inability to bear weight if lower extremity involved
• Imaging correlates: diaphyseal or metadiaphyseal location (unlike osteosarcoma's metaphyseal predilection); femur, pelvis, tibia most common; "onion skin" (lamellated) periosteal reaction or aggressive periosteal response; mixed lytic/sclerotic or purely lytic lesion; large soft tissue mass often disproportionate to intraosseous component (aggressive extraosseous extension); MRI shows marrow replacement by intermediate T2 signal (cellular tumor, less edema than infection); may be mistaken for acute osteomyelitis (indeed, this is a common board trap—clinical context and biopsy essential for distinction)
• Constitutional symptoms and fever should raise suspicion for Ewing even when imaging and clinical presentation overlap with infection
• Staging: PET-CT and chest CT (pulmonary mets in ~80% of cases at diagnosis or developed during course); bone marrow biopsy to evaluate occult marrow involvement (prognostic significance)

• Chondrosarcoma:
• Painless or mildly painful swelling that progresses slowly over months to years; pain, when present, suggests **grade III

• Non-aggressive pattern: narrow zone of transition, sclerotic rim, intact cortex, no periosteal reaction — favors osteochondroma, enchondroma, osteoid osteoma, non-ossifying fibroma.
• Aggressive pattern: wide/indistinct zone of transition (permeative or moth-eaten), cortical destruction, soft-tissue mass, and aggressive periosteal reaction (Codman triangle, sunburst, onion-skin) — mandates referral before any intervention. This lytic-margin descriptive scheme is the Lodwick classification.

• Ancillary testing: membranous CD99 (MIC2) immunostaining and EWSR1 rearrangement by FISH/RT-PCR for Ewing; malignant osteoid production defines osteosarcoma regardless of grade.

Immediate issues to address first

• Impending or completed pathologic fracture: immobilize and avoid weight-bearing; do not internally fix a fracture through an undiagnosed lesion, as intramedullary instrumentation contaminates the entire canal and forfeits limb salvage.
• Spinal cord compression from a vertebral lesion: dexamethasone plus emergent neurosurgical/radiation oncology consultation.

Benign lesions

• Osteochondroma: observation if asymptomatic; marginal excision including the cartilage cap and perichondrium for mechanical symptoms or suspected transformation.
• Osteoid osteoma: NSAIDs (e.g., ibuprofen) are both diagnostic and definitive, since many lesions involute over years; CT-guided percutaneous radiofrequency ablation of the nidus is the standard intervention for refractory pain.
• Giant cell tumor of bone: intralesional curettage with a high-speed burr plus an adjuvant (phenol, liquid nitrogen, or cement) is first-line. For unresectable, axial, or metastatic disease, the RANKL inhibitor denosumab is FDA-approved and reflected in NCCN Bone Cancer recommendations; it is used cautiously as a neoadjuvant because it hardens the tumor rim and obscures margins. Radiation is generally avoided because of sarcomatous transformation risk.

Malignant tumors (NCCN Bone Cancer guidelines, multidisciplinary sarcoma center)

• Osteosarcoma: neoadjuvant multiagent chemotherapy — MAP (high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin) — followed by wide en-bloc resection with limb salvage where feasible, then adjuvant chemotherapy. Percent tumor necrosis in the resected specimen (Huvos grading; ≥90% is favorable) is the key prognostic readout. Osteosarcoma is relatively radioresistant, so radiation is reserved for unresectable sites.
• Ewing sarcoma: chemotherapy first for all patients, classically vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE), then local control by surgery, radiation, or both — Ewing is uniquely radiosensitive.
• Chondrosarcoma: wide surgical resection is the only curative modality; conventional chondrosarcoma is largely chemotherapy- and radiation-resistant, and giving cytotoxic chemotherapy for conventional grade 1–2 disease is a classic error (dedifferentiated and mesenchymal variants are the exceptions).

Disease-related

• Pathologic fracture: cortical destruction removes structural bone; signaled by sudden severe pain after trivial trauma with a lucent lesion at the fracture line. Urgent — mishandling forfeits limb salvage.
• Pulmonary metastasis: hematogenous spread through thin-walled marrow sinusoids; new dyspnea, hemoptysis, or *cannonball*/nodular lesions on chest CT. The dominant cause of death in osteosarcoma and Ewing sarcoma.
• Metastatic epidural cord compression: back pain with myelopathy, saddle anesthesia, or retention — a neurosurgical emergency.
• Malignant transformation: osteochondroma to secondary chondrosarcoma (cartilage cap thickening or renewed growth after skeletal maturity), and sarcomatous change in Paget disease or an irradiated field.
• Local recurrence: highest with intralesional margins; giant cell tumor recurs in the curettage cavity, and rare benign pulmonary implants can occur.

Treatment-related

• Doxorubicin cardiotoxicity: free-radical and topoisomerase-2β–mediated myocyte injury, cumulative and dose-dependent; falling LVEF on surveillance echocardiography, later overt HFrEF. If HFrEF develops, guideline-directed therapy per ACC/AHA is four classes — ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor.
• Cisplatin: proximal tubular injury with magnesium wasting, and irreversible high-frequency sensorineural hearing loss — audiometry is monitored during therapy.
• High-dose methotrexate: crystalline tubular precipitation and mucositis; prevented by urinary alkalinization, hydration, and leucovorin rescue. Delayed clearance with a rising creatinine is an emergency (glucarpidase).
• Ifosfamide: acrolein-mediated hemorrhagic cystitis (prevent with mesna and hydration) and encephalopathy; also Fanconi syndrome.
• Cyclophosphamide/etoposide plus radiation: secondary MDS/AML and radiation-induced sarcoma years later.
• Febrile neutropenia: an oncologic emergency requiring blood cultures and empiric antipseudomonal beta-lactam therapy within an hour, per IDSA neutropenic fever guidance.
• Denosumab: profound RANKL blockade causes hypocalcemia and osteonecrosis of the jaw; rebound osteoclast activation on discontinuation.
• Surgical: endoprosthetic infection, aseptic loosening, and limb-length discrepancy in skeletally immature patients.

• Radiograph first, always: for any bone pain plus a mass, the single best next step is a plain film — never biopsy or MRI first, and never internally fix a fracture through an uncharacterized lytic lesion.
• Location decides the differential: epiphysis in a 20–40-year-old = giant cell tumor (soap-bubble lytic lesion abutting subchondral bone); metaphysis around the knee in a teenager = osteosarcoma (Codman triangle, sunburst); diaphysis of femur/pelvis in an adolescent = Ewing sarcoma (onion-skin lamellated periosteum).
• The association examiners test most: Ewing sarcoma's t(11;22)(q24;q12) EWSR1–FLI1 fusion with small round blue cells and membranous CD99. For osteosarcoma, the pairing is germline TP53 (Li-Fraumeni) and RB1 (hereditary retinoblastoma survivors).
• Defining histology beats imaging: malignant cells producing osteoid = osteosarcoma by definition, at any grade or site.
• The classic distractor: a febrile adolescent with a painful, warm diaphyseal lesion, elevated ESR/CRP, and leukocytosis is Ewing sarcoma masquerading as osteomyelitis — biopsy, not antibiotics alone, settles it. Likewise, small round blue cell mimics include lymphoma, neuroblastoma metastasis, and rhabdomyosarcoma.
• Osteoid osteoma: nidus <2 cm with reactive sclerosis, night pain dramatically relieved by NSAIDs (prostaglandin-mediated). Osteoblastoma is >2 cm, favors posterior vertebral elements, and responds poorly to NSAIDs.
• Age flips the cartilage answer: a young patient with a cartilage lesion has an enchondroma or osteochondroma; an adult over 40 with a painful pelvic or proximal femoral cartilage lesion with endosteal scalloping has chondrosarcoma. Pain in a cartilage lesion is the red flag.
• Treatment traps: chondrosarcoma is treated by wide resection, not chemotherapy or radiation; osteosarcoma and Ewing both get neoadjuvant chemotherapy, but only Ewing is radiosensitive; giant cell tumor is treated with curettage or denosumab, not radiation.